comparemela.com
Home
Live Updates
ESC Backs SGLT2i Plus GLP-1 in Diabetes with High CVD Risk : comparemela.com
ESC Backs SGLT2i Plus GLP-1 in Diabetes with High CVD Risk
New ESC guidelines recommend using both an SGLT2 inhibitor and a GLP-1 receptor agonist simultaneously to treat people with type 2 diabetes and established cardiovascular disease.
Related Keywords
Texas
,
United States
,
Cambridge
,
Cambridgeshire
,
United Kingdom
,
Amsterdam
,
Noord Holland
,
Netherlands
,
Dallas
,
American
,
Naveed Sattar
,
Darrenk Mcguire
,
Astrazeneca
,
Novo Nordisk
,
Boehringer Ingelheim
,
Ut Southwestern Medical Center
,
American Diabetes Association
,
European Society Of Cardiology
,
Amgen
,
University Of Glasgow
,
Novartis
,
University Of Cambridge
,
Pfizer
,
European Society
,
Medical Center
,
Diabetes Risk
,
Emanuele Di Angelantonio
,
Deputy Director
,
Cardiovascular Epidemiology Unit
,
Applied Therapeutics
,
New Amsterdam
,
Presented August
,
Cv
,
Ardiovascular
,
Diabetes Mellitus Type 2
,
Iabetes Mellitus Type Ii
,
Type 2 Diabetes
,
Glp 1 Receptor Agonists
,
Glucagon Like Peptide 1 Receptor Agonists
,
Clinical Guidelines
,
Guidelines
,
Heart Failure
,
Receptors
,
Cardiovascular Disease
,
Vd Cardiovascular Disease
,
Europe
,
European
,
Heart
,
Chronic Renal Failure
,
Hronic Kidney Failure
,
Hronic Kidney Disease Ckd
,
Chronic Kidney Disease
,
Kd
,
Renal Fa
,
comparemela.com © 2020. All Rights Reserved.